Glucagon News and Research

RSS

Two isoforms of a cellular energy sensor play distinct, opposing roles in Alzheimer's disease

A comprehensive mini-review published today after peer review in Brain Medicine by Dr. Tao Ma and colleagues at Wake Forest University School of Medicine synthesizes emerging evidence that two isoforms of a critical cellular energy sensor play distinct, and sometimes opposing, roles in Alzheimer's disease.

6 Jan 2026

How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOS

This review synthesizes evidence that gut microbiota dysbiosis contributes to insulin resistance and symptom severity in polycystic ovary syndrome through impaired barrier function, inflammation, and altered microbial metabolites. It evaluates how Traditional Chinese Medicine may modulate these pathways while highlighting major gaps in clinical validation, safety, and standardization.

16 Dec 2025

Swapping high-carb snacks for tree nuts cuts food cravings in young adults at metabolic risk

Daily replacement of typical high-carbohydrate snacks with mixed tree nuts for 16 weeks reduced cravings for sweets and fast foods in young adults with early metabolic syndrome risk. This dietary swap improved overall diet quality, measured by the Healthy Eating Index, without increasing body weight or altering short-term glycaemic markers.

14 Dec 2025

What happens to your body during an ultramarathon? New study reveals key metabolic changes

This study tracked ultramarathon runners across 100 km, 160.9 km, and 230 km events to examine real-world metabolic, hormonal, and muscle stress responses. Severe energy deficits, muscle damage, and heterogeneous hormonal shifts were observed, with the greatest strain seen in the 230 km distance.

10 Dec 2025

Glucose-lowering drugs may reduce risk of developing epilepsy

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

In adults with stage IIIb–IV chronic kidney disease, the constipation drug lubiprostone did not reduce gut-derived uremic toxins but preserved creatinine-based kidney function over 24 weeks. The benefit was linked to microbiome remodeling, increased polyamine production, and improved mitochondrial function rather than toxin lowering.

8 Dec 2025

Diabetes drugs linked to slower frailty progression in older adults

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors-such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)-or glucagon-like peptide-1 (GLP-1) receptor agonists-such as semaglutide (Ozempic) and liraglutide (Victoza)-experience slower progression of frailty over one year compared with those starting other diabetes medications.

3 Dec 2025

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

To address the growing global health challenge of obesity, which affects more than 1 billion people, the World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.

2 Dec 2025

Brain recordings reveal why food cravings return despite tirzepatide

Researchers investigate the effects of tirzepatide on food preoccupation by influencing the brain’s mesolimbic circuitry.

1 Dec 2025

Stopping GLP-1 drugs before pregnancy leads to more weight gain

Researchers determine the risk of pregnancy weight gain in patients who were prescribed GLP-1 RAs prior to conception.

1 Dec 2025

Semaglutide helps older adults lose weight without immediate bone loss

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to assess its effects on bone health.

1 Dec 2025

Regenerative medicine offers a pathway toward curing type 1 diabetes

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic β-cells.

26 Nov 2025

Metformin fails to improve insulin resistance in type 1 diabetes

Metformin treatment in type 1 diabetes lowers insulin dosage but does not improve insulin resistance, highlighting its complex role in diabetes management.

26 Nov 2025

GLP-1 discontinuation associated with more weight gain and pregnancy complications

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more weight and have higher risks of diabetes and hypertensive disorders during pregnancy, and experienced preterm delivery more so than people who had never taken GLP-1 drugs.

24 Nov 2025

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Researchers showed that GLP-1 receptor agonism counteracts aging across multiple organs in mice, improving strength and reversing molecular aging signatures without meaningful effects on body weight. These benefits depended largely on hypothalamic GLP-1R signaling and closely mirrored the anti-aging patterns produced by rapamycin.

23 Nov 2025

Oral GLP-1 pill shows strong weight loss and blood sugar benefits in adults with diabetes

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.

20 Nov 2025

Searches for “Ozempic face” surge as people look for filler-based solutions

Public interest in “Ozempic face” rose sharply from 2022 to 2025, mirrored by increased searches for nonsurgical facial filler procedures. Surgical terms showed neutral or negative associations, indicating consumers are primarily exploring filler-based solutions for GLP-1RA-related facial volume loss.

20 Nov 2025

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects.

20 Nov 2025

Glucagon News and Research

Two isoforms of a cellular energy sensor play distinct, opposing roles in Alzheimer's disease

How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOS

Swapping high-carb snacks for tree nuts cuts food cravings in young adults at metabolic risk

What happens to your body during an ultramarathon? New study reveals key metabolic changes

Glucose-lowering drugs may reduce risk of developing epilepsy

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

Diabetes drugs linked to slower frailty progression in older adults

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

Brain recordings reveal why food cravings return despite tirzepatide

Stopping GLP-1 drugs before pregnancy leads to more weight gain

Semaglutide helps older adults lose weight without immediate bone loss

Regenerative medicine offers a pathway toward curing type 1 diabetes

Metformin fails to improve insulin resistance in type 1 diabetes

GLP-1 discontinuation associated with more weight gain and pregnancy complications

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Oral GLP-1 pill shows strong weight loss and blood sugar benefits in adults with diabetes

Searches for “Ozempic face” surge as people look for filler-based solutions

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News